Alzheimer’s Disease and Related Disorders (ADRD) are public health crises and critical areas of scientific effort. The National Institutes of Health, Alzheimer’s Association, and other federal, state, and non-profit funders of research are investing heavily in the science of ADRD in an effort to curb the impact of these debilitating, burdensome, and costly disorders. Tremendous advances made in understanding the pathobiology of disease will ultimately have one final pathway to impacting clinical care and public health – randomized controlled clinical trials.
IMPACT-AD was founded to train the next generation of ADRD clinical trialists, to ensure that investments in discovery yield outcomes for patients and families. Our goal is to provide education and tools to establish a national cohort of qualified investigators to guide the field toward improved therapies. Equally importantly, we are focused on diversifying the ADRD trial workforce. This diversity is manifold: it includes the demographic characteristics of investigators (age, race, ethnicity, etc.), but also their specialties (physicians, psychologists, statisticians, etc.), backgrounds (rural, urban, etc.), and career stage or current position (current AD Clinical Trial Consortium (ACTC) site, non-ACTC academic site, non-academic site). IMPACT-AD will be successful if it produces an outstanding, well-trained, diverse, and knowledgeable cohort of collaborative investigators who will carry the mantle of the National Plan to Address AD.
IMPACT-AD will leverage the outstanding collection of investigators, including members of the ACTC and beyond. National and international leaders in ADRD trials will gather annually to provide a unique, interactive, cutting edge educational experience in ADRD trials. We offer two tracks for those interested in advancing their careers in ADRD trials.
Rema Raman, PhD
Joshua Grill, PhD